Chapter 17: Antidepressant Medications

The chapter distinguishes among six major classes of antidepressants including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, norepinephrine reuptake inhibitors, and atypical antidepressants, each operating through distinct neurochemical mechanisms. Understanding these mechanisms requires knowledge of how antidepressants increase the availability of serotonin, norepinephrine, and dopamine in synaptic spaces to enhance mood regulation and emotional processing. The chapter addresses common adverse effects including sexual dysfunction, weight gain, emotional blunting, and serotonin syndrome, which significantly influence treatment adherence and medication selection. Treatment-resistant depression is discussed as a clinical challenge requiring augmentation strategies, dose optimization, or switching between medication classes. A critical emphasis is placed on bipolar disorder management, particularly the risk that antidepressants can precipitate manic episodes without concurrent mood stabilizer therapy, necessitating careful diagnostic assessment before prescribing. The chapter outlines three treatment phases including acute intervention for symptom reduction, continuation therapy to consolidate improvements, and maintenance treatment for long-term relapse prevention. Throughout the discussion, the importance of individualized treatment planning emerges, considering patient-specific factors such as symptom presentation, medical comorbidities, prior medication responses, and tolerance profiles. The integration of pharmacological and psychological interventions is presented as optimal clinical practice, recognizing that medication alone represents incomplete treatment for most depressive conditions.